Related Experiment Videos

New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice

¹Cardiovascular Thrombosis Research Center, University of Massachusetts Medical Center, Worcester, Massachusetts 01655, USA. richard.becker@banyan.ummed.edu.

Journal of Thrombosis and Thrombolysis

|June 12, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

The effect of the REG2 Anticoagulation System on thrombin generation kinetics: a pharmacodynamic and pharmacokinetic first-in-human study.

Journal of thrombosis and thrombolysis·2014

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.

Journal of clinical pharmacology·2014

A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent.

Journal of thrombosis and haemostasis : JTH·2012

Antidote control of aptamer therapeutics: the road to a safer class of drug agents.

Current pharmaceutical biotechnology·2012

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

Journal of thrombosis and thrombolysis·2011

Viscous Rayleigh-Taylor instability experiments at high pressure and strain rate.

Physical review letters·2010

See all related articles